SER (Serina Therapeutics, Inc.) Stock Analysis - SEC Filings

Serina Therapeutics, Inc. (SER) is a publicly traded Healthcare sector company. As of May 21, 2026, SER trades at $1.71 with a market cap of $22.65M and a P/E ratio of -0.90. SER moved +5.59% today. Year to date, SER is -18.27%; over the trailing twelve months it is -70.23%. Its 52-week range spans $1.22 to $8.14. Analyst consensus is buy with an average price target of $11.00. Rallies surfaces SER's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Where can I find SER SEC filings?

Rallies organizes SER SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.

SER Key Metrics

Key financial metrics for SER
MetricValue
Price$1.71
Market Cap$22.65M
P/E Ratio-0.90
EPS$-1.91
Dividend Yield0.00%
52-Week High$8.14
52-Week Low$1.22
Volume91
Avg Volume0
Revenue (TTM)$130.00K
Net Income$-19.21M
Gross Margin0.00%

Latest SER News

Recent SER Insider Trades

  • Moreadith Randall sold 6.50K (~$18.57K) on Mar 23, 2026.
  • Moreadith Randall sold 39.00K (~$97.50K) on Mar 19, 2026.
  • Moreadith Randall sold 6.50K (~$19.68K) on Feb 2, 2026.

SER Analyst Consensus

1 analysts cover SER: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $11.00.

Common questions about SER

Where can I find SER SEC filings?
Rallies organizes SER SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
Does Rallies show SER 10-K and 10-Q filings?
Rallies organizes SER SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.
Is SER research on Rallies investment advice?
No. Rallies provides research, data, and educational context for SER. It does not provide personalized investment advice.
SER

SER